Ocular Therapeutix Inc - No Patients in Axpaxli Group Experienced Worsening in Drss Compared to 12.5% in Control Arm at 40 Weeks
Ocular Therapeutix Inc-Axpaxli组中没有患者的病情恶化,而对照组在40周时这一比例为12.5%
Ocular Therapeutix Inc - No Patients in Axpaxli Group Experienced Worsening in Drss Compared to 12.5% in Control Arm at 40 Weeks
Ocular Therapeutix Inc-Axpaxli组中没有患者的病情恶化,而对照组在40周时这一比例为12.5%
使用浏览器的分享功能,分享给你的好友吧